血浆游离DNA在恶性肿瘤诊疗中的应用

doi:10.3760/cma.j.issn.1673-422X.2014.03.006

摘要/Abstract

摘要： 【摘要】肿瘤患者血浆游离DNA（cfpDNA）不仅在总量上明显增加，还携带有与原发肿瘤相同的基因变化，能够反映肿瘤细胞生物学特性、发生发展及预后，是一种新的肿瘤标志物，检测cfpDNA变化对肿瘤临床诊断、疗效和预后监测都有十分重要的参考价值。

关键词: 肿瘤, 肿瘤标记, 生物学, 血浆游离DNA

Abstract: cellfree plasma DNA (cfpDNA) has been suggested as a useful tumor marker for its quantitative and qualitative tumorspecific alterations that reflect the biological characteristics and the progression and outcomes of tumors. Therefore, it has been used as liquid biopsy to detect cfpDNA in peripheral blood for the diagnosis, monitoring of clinical effects, and prognosis of malignancies

Key words: Neoplasms, Tumor markers, biological, Cellfree plasma DNAThe

朱响, 吴晖, 袁爱华, 杨坤兴, 曹红勇. 血浆游离DNA在恶性肿瘤诊疗中的应用[J]. 国际肿瘤学杂志, 2014, 41(3): 180-183.

ZHU Xiang, WU Hui, YUAN Ai-Hua, YANG Kun-Xing, CAO Hong-Yong. Application of the cellfree plasma DNA in the diagnosis and treatment of malignancies[J]. Journal of International Oncology, 2014, 41(3): 180-183.

参考文献

［1］ Anker P, Stroun M. Circulating nucleic acids and evolution［J］. Expert Opin Biol Ther， 2012， 12Suppl 1:S113-117. ［2］ GonzálezMasiá JA, GarcíaOlmo D, GarcíaOlmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology［J］. Onco Targets Ther， 2013， 6:819-832. ［3］ Jung K, Fleischhacker M, Rabien A. Cellfree DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature［J］. Clin Chim Acta, 2010,411(2122):1611-1624. ［4］ Suzuki N, Kamataki A, Yamaki J, et al. Characterization of circulating DNA in healthy human plasma［J］. Clin Chim Acta, 2008,387(1-2):55-58. ［5］ Li CN, Hsu HL, Wu TL, et al. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines［J］. J Clin Lab Anal， 2003， 17(4):103-107. ［6］ Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients［J］. Expert Opin Biol Ther， 2012， 12Suppl 1:S209-215. ［7］ Skvortsova TE, Vlassov VV, Laktionov PP. Binding and penetration of methylated DNA into primary and transformed human cells［J］. Ann N Y Acad Sci， 2008， 1137:36-40. ［8］ van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?［J］. Clin Biochem, 2010, 43(1-2):26-36. ［9］ Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in nonsmall cell lung cancer［J］. Lung Cancer， 2009， 64(1):92-97. ［10］ Altimari A, Grigioni AD, Benedettini E, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer［J］. Am J Clin Pathol, 2008, 129(5):756-762. ［11］ Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors［J］. Mol Cancer， 2009, 8:105. ［12］ Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients［J］. Nat Rev Cancer， 2011， 11(6):426-437. ［13］ Zhang R, Shao F, Wu X, et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis［J］. Lung Cancer, 2010, 69(2):225-231. ［14］ Wimberger P, Roth C, Pantel K, et al. Impact of platinumbased chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients［J］. Int J Cancer， 2011， 128(11):2572-2580. ［15］ Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients［J］. Cancer Res， 2003， 63(14):3966-3968. ［16］ Holdenrieder S, Burges A, Reich O, et al. DNA integrity in plasma and serum of patients with malignant and benign diseases［J］. Ann N Y Acad Sci, 2008, 1137:162-170. ［17］ ElShazly SF, Eid MA, El-Sourogy HA, et al. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virusrelated hepatocellular carcinoma［J］. Int J Biol Markers, 2010, 25(2):79-86. ［18］ Chen Z, Feng J, Buzin CH, et al. Analysis of cancer mutation signatures in blood by a novel ultrasensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer［J］. PLoS One， 2009， 4(9):e7220. ［19］ Wade M, Li YC, Wahl GM. MDM2,MDMX and p53 in oncogenesis and cancer therapy［J］. Nat Rev Cancer, 2013, 13(2):83-96. ［20］ Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics［J］. Nat Med， 2008， 14(9):985-990. ［21］ Mirza S, Sharma G, Parshad R, et al. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients［J］. Ann Surg Oncol, 2012, 19(9):3107-3115. ［22］ Melnikov A, Scholtens D, Godwin A, et al. Differential methylation profile of ovarian cancer in tissues and plasma［J］. J Mol Diagn, 2009, 11(1):60-65. ［23］ Shah SN, Hile SE, Eckert KA. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes［J］. Cancer Res， 2010， 70(2):431-435. ［24］ Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades［J］. Neuro Oncol, 2010, 12(2):173-180. ［25］ von Knobloch R, Hegele A, Brandt H, et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis［J］. Int J Cancer, 2001, 94(1):67-72. ［26］ Duffy MJ, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers (EGTM) 2014 guidelines update［J］. Int J Cancer， 2013， In Press. ［27］ Rawnaq T, Schwarzenbach H, Schurr PG, et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence［J］. J Surg Res, 2011, 169(1):31-35. ［28］ Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cellfree DNA from plasma and serum［J］. Clin Chim Acta， 2009， 404(2):100-104. ［29］ Szpechcinski A, Struniawska R, Zaleska J, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients［J］. J Physiol Pharmacol， 2008， 59Suppl 6:675-681.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.